First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases
We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which va...
Gespeichert in:
| Veröffentlicht in: | Chemical communications (Cambridge, England) England), 2020-08, Vol.56 (67), p.9695-9698 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9698 |
|---|---|
| container_issue | 67 |
| container_start_page | 9695 |
| container_title | Chemical communications (Cambridge, England) |
| container_volume | 56 |
| creator | Gabr, Moustafa T Barbault, Florent |
| description | We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.
We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. |
| doi_str_mv | 10.1039/d0cc04249h |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_rsc_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_2426537654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426537654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-3e01ef742d1fa10cc2aaa7a2dc031e0fff8023eb8fe2af6d6c2e27c232948ea43</originalsourceid><addsrcrecordid>eNp90ctrFTEUB-BBFPvQjXsl4kaE0bwmM-Ou3NpWKAqi4G44NznpTZmZTPMouPcPN7e3D3DRbBI4H4dz8quqV4x-ZFT0nwzVmkou-82Tap8JJetGdr-fbt9NX7dCNnvVQYyXtBzWdM-rPcFV33dK7Fd_T1yIiZgMI1m72WAg3pLJ6eB_fDuqmVRAYDZk8rOfMDhNEuTPBMjsr3EksCzBg94Q6wOZ8phcgnCBCQ1JGwywYE5Ox5vyjDl4gxc4l0Jy10iMiwgR44vqmYUx4svb-7D6dfLl5-qsPv9--nV1dF5roUSqBVKGtpXcMAusLM0BoAVuNBUMqbW2o1zgurPIwSqjNEfeai54LzsEKQ6r97u-ZeirjDENk4saxxFm9DkOXHLViFY1W_ruP3rpc5jLdEWJpmFKdFv1YafKd8UY0A5LcBOEPwOjwzab4ZiuVjfZnBX85rZlXk9o7uldGAW83YEQ9X31IdxhMbaY148Z8Q_vu6Cy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435516384</pqid></control><display><type>article</type><title>First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><source>Alma/SFX Local Collection</source><creator>Gabr, Moustafa T ; Barbault, Florent</creator><creatorcontrib>Gabr, Moustafa T ; Barbault, Florent</creatorcontrib><description>We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.
We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a.</description><identifier>ISSN: 1359-7345</identifier><identifier>EISSN: 1364-548X</identifier><identifier>DOI: 10.1039/d0cc04249h</identifier><identifier>PMID: 32699863</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - pathology ; Alzheimer's disease ; Cell Line ; Cell Survival - drug effects ; Humans ; Kinetics ; MicroRNAs ; MicroRNAs - chemistry ; MicroRNAs - metabolism ; Molecular Conformation ; Neuroprotective Agents - chemistry ; Neuroprotective Agents - metabolism ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; Protein Binding ; Ribonucleic acid ; RNA ; tau Proteins - chemistry ; tau Proteins - metabolism</subject><ispartof>Chemical communications (Cambridge, England), 2020-08, Vol.56 (67), p.9695-9698</ispartof><rights>Copyright Royal Society of Chemistry 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-3e01ef742d1fa10cc2aaa7a2dc031e0fff8023eb8fe2af6d6c2e27c232948ea43</citedby><cites>FETCH-LOGICAL-c363t-3e01ef742d1fa10cc2aaa7a2dc031e0fff8023eb8fe2af6d6c2e27c232948ea43</cites><orcidid>0000-0001-9074-3331</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32699863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gabr, Moustafa T</creatorcontrib><creatorcontrib>Barbault, Florent</creatorcontrib><title>First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases</title><title>Chemical communications (Cambridge, England)</title><addtitle>Chem Commun (Camb)</addtitle><description>We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.
We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer's disease</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Humans</subject><subject>Kinetics</subject><subject>MicroRNAs</subject><subject>MicroRNAs - chemistry</subject><subject>MicroRNAs - metabolism</subject><subject>Molecular Conformation</subject><subject>Neuroprotective Agents - chemistry</subject><subject>Neuroprotective Agents - metabolism</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Protein Binding</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>tau Proteins - chemistry</subject><subject>tau Proteins - metabolism</subject><issn>1359-7345</issn><issn>1364-548X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90ctrFTEUB-BBFPvQjXsl4kaE0bwmM-Ou3NpWKAqi4G44NznpTZmZTPMouPcPN7e3D3DRbBI4H4dz8quqV4x-ZFT0nwzVmkou-82Tap8JJetGdr-fbt9NX7dCNnvVQYyXtBzWdM-rPcFV33dK7Fd_T1yIiZgMI1m72WAg3pLJ6eB_fDuqmVRAYDZk8rOfMDhNEuTPBMjsr3EksCzBg94Q6wOZ8phcgnCBCQ1JGwywYE5Ox5vyjDl4gxc4l0Jy10iMiwgR44vqmYUx4svb-7D6dfLl5-qsPv9--nV1dF5roUSqBVKGtpXcMAusLM0BoAVuNBUMqbW2o1zgurPIwSqjNEfeai54LzsEKQ6r97u-ZeirjDENk4saxxFm9DkOXHLViFY1W_ruP3rpc5jLdEWJpmFKdFv1YafKd8UY0A5LcBOEPwOjwzab4ZiuVjfZnBX85rZlXk9o7uldGAW83YEQ9X31IdxhMbaY148Z8Q_vu6Cy</recordid><startdate>20200820</startdate><enddate>20200820</enddate><creator>Gabr, Moustafa T</creator><creator>Barbault, Florent</creator><general>Royal Society of Chemistry</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>L7M</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9074-3331</orcidid></search><sort><creationdate>20200820</creationdate><title>First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases</title><author>Gabr, Moustafa T ; Barbault, Florent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-3e01ef742d1fa10cc2aaa7a2dc031e0fff8023eb8fe2af6d6c2e27c232948ea43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer's disease</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Humans</topic><topic>Kinetics</topic><topic>MicroRNAs</topic><topic>MicroRNAs - chemistry</topic><topic>MicroRNAs - metabolism</topic><topic>Molecular Conformation</topic><topic>Neuroprotective Agents - chemistry</topic><topic>Neuroprotective Agents - metabolism</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Protein Binding</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>tau Proteins - chemistry</topic><topic>tau Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gabr, Moustafa T</creatorcontrib><creatorcontrib>Barbault, Florent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical communications (Cambridge, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gabr, Moustafa T</au><au>Barbault, Florent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases</atitle><jtitle>Chemical communications (Cambridge, England)</jtitle><addtitle>Chem Commun (Camb)</addtitle><date>2020-08-20</date><risdate>2020</risdate><volume>56</volume><issue>67</issue><spage>9695</spage><epage>9698</epage><pages>9695-9698</pages><issn>1359-7345</issn><eissn>1364-548X</eissn><abstract>We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.
We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>32699863</pmid><doi>10.1039/d0cc04249h</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-9074-3331</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-7345 |
| ispartof | Chemical communications (Cambridge, England), 2020-08, Vol.56 (67), p.9695-9698 |
| issn | 1359-7345 1364-548X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2426537654 |
| source | MEDLINE; Royal Society Of Chemistry Journals 2008-; Alma/SFX Local Collection |
| subjects | Alzheimer Disease - drug therapy Alzheimer Disease - pathology Alzheimer's disease Cell Line Cell Survival - drug effects Humans Kinetics MicroRNAs MicroRNAs - chemistry MicroRNAs - metabolism Molecular Conformation Neuroprotective Agents - chemistry Neuroprotective Agents - metabolism Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Protein Binding Ribonucleic acid RNA tau Proteins - chemistry tau Proteins - metabolism |
| title | First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_rsc_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20dual%20binder%20of%20microRNA-146a%20and%20monomeric%20tau:%20a%20novel%20approach%20for%20multitargeted%20therapeutics%20for%20neurodegenerative%20diseases&rft.jtitle=Chemical%20communications%20(Cambridge,%20England)&rft.au=Gabr,%20Moustafa%20T&rft.date=2020-08-20&rft.volume=56&rft.issue=67&rft.spage=9695&rft.epage=9698&rft.pages=9695-9698&rft.issn=1359-7345&rft.eissn=1364-548X&rft_id=info:doi/10.1039/d0cc04249h&rft_dat=%3Cproquest_rsc_p%3E2426537654%3C/proquest_rsc_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435516384&rft_id=info:pmid/32699863&rfr_iscdi=true |